Albumin and fibrinogen show no binding affinity to varied molecular weights ofhepafin at physiological pH. Human plasma fibronectin was shown to bind heparins in both the solution and adsorbed states. Fibronectin was shown to have six active binding sites for heparins which may be stericaUy blocked in some adsorbed states. 125I-Fibronectin monolayer concentrations were shown to be significantly different on polyvinyl chloride surfaces when compared to hydrophilic/hydrophobic silica, Biomer, Silastic, and polystyrene surfaces. Preadsorbing fibronectin to various substrates and then allowing heparins to interact with the protein monolayer made it possible to bind up to 0.2 t~g/cm 2 heparin in a plasma environment. This fibronectin-heparin complex was at least 85% stable in plasma and buffer solutions for up to 8 h time. The complex was observed to prolong blood clotting times two to three times over that of controls as assayed by Activated Partial Thromboplastin Times. All of the bound heparin was observed to be active by its ability to bind Factor X, in plasma. Monolayers of blood proteins adsorbed from human serum were not observed to be active in binding heparins. The fibronectin-heparin conjugate showed low activation of blood components compared to protein monolayers preadsorbed from human sera as assayed by Activated Partial Thromboplastin Time.
INTRODUCTION
Great advances have been made during the past decade toward the concept of rendering biomaterials nonthrombogenic (1, 2) . It has been proposed that relationships exist between the blood compatibility of foreign substrates and substrate characteristics, such as surface charge, hydrophilicity, surface-free energy, and surface protein interactions (3), Probably the most important unresolved problem with blood-contacting devices is that these devices are not as biologically compatible (inactive) with blood as blood is with the endothelial lin-with a relative abundance of absorbed fibrinogen or gamma-globulin (y-globulin) (3, (5) (6) (7) . In these studies, platelet adherence to adsorbed albumin and other adsorbed nonglycoproteins did not occur, due possibly to a lack of carbohydrate moieties, which are plentiful in fibrinogen and 7-globulins (8) . Platelet adhesion and the resultant morphological changes seem to be determined both by the composition and the conformation of the initially adsorbed protein monolayer (9) . The preferential adsorption of albumin, or maintenance of a preadsorbed albumin monolayer requires that implanted surfaces be passive to most proteins yet "recognize" albumin and bind to it (10) . This usually requires surface modification since most surfaces do not preferentially adsorb albumin (11) (12) (13) (14) (15) .
Methodology (a) above is unique in that it ignores most of the surface effects associated with blood-containing devices and instead focuses upon the bulk properties of the substrate to inhibit surface-induced thrombosis. The hypothesis is that moduli differences are what the body responds to in the activation of the intrinsic coagulation pathway. This methodology, like (b), requires new or modified materials to obtain the required bulk and surface characteristics.
The methodologies listed in (c) and (d) are accomplished by inhibiting platelet adhesion and aggregation and fibrin formation via pharmaceutical approaches. Using platelet and coagulation inhibitors, in conjunction with the medical devices, it is possible to improve blood compatibility by blocking the inherent mechanisms that are the driving force for these normal physiological functions. However, systemic usage of these inhibitors at physiologically necessary concentrations could prove fatal; i.e., vascular hemorrhage would remain unchecked by both coagulation or platelet adhesion. Recognition of this problem has resulted in several unique and innovative approaches for local delivery of small doses of either platelet inhibitors, coagulation inhibitors, or both, in concentrations too low to have bulk effect (16) . The most prevalent drug being currently delivered in this fashion is heparin. However, prostaglandins and urokinase (17) have also been utilized successfully for their antiplatelet and fibrinolytic activities, respectively.
A novel approach by Henninck et al. (18) to evaluate both antiplatelet activity and anticoagulation has been made utilizing the natural driving force of protein adsorption to decrease surface-free energy. Heparin is delivered onto a medical device using the protein which itself reduces platelet adhesion (7, (19) (20) (21) . In this methodology, heparin is covalently bound to albumin and preadsorbed to implantable polymers. The albumin coverage inhibits platelet adhesion and retention on the substrate surface while the immobilized heparin inactivates the coagulation cascade on a localized level.
Using this last approach as a type model, it may be possible to improve upon it by preadsorbing blood proteins, that have a natural affinity to heparin, onto medical grade materials. Heparin is then bound to the adsorbed protein monolayer in sufficient quantity to cause a localized inhibition of the coagulation cascade and a resultant depressed platelet response. The advantages of this technique are several fold: (i) there is no compromising of the heparin or protein structure by covalenfly altering either one; (ii) there is no compromising of the substrate surface or extended chemistries to covalenfly link the heparin or protein to the surface of interest; (iii) the adoption of a "naturally" occurring physiological phenomenon; (iv) no toxicological side effects from extraneous chemical reactions; (v) no chemical modification of the surface of interest--this allows for choices of materials with desirable mechanical properties without worrying about needed preferential adsorption of specific proteins; and (vi) ease of preparation. In case (iii) the naturally occurring adsorption of serum proteins is used to reduce the surface energy of a blood-contacting medical device followed by affinity binding of heparin to the protein. This process (iii) and resultant protein-heparin ligand may not be physiologically viewed as an antigen thereby having antibodies produced against it.
MATERIALS AND METHODS
Biomer (Ethicon Inc., Somerville, N.J.) was received as a 30% by weight (w/v) solution in N,N-dimethylacetamide (DMAC). The solution was diluted to a 15% (w/v) solution in DMAC (Baker Chemical, Phillipsburg, N.J.) and precipitated in distilled water. The polymer precipitate was thoroughly washed, dried, and vacuum-dessicated for 12 h at room temperature. The dried polymer precipitate was stored in the dark, at room temperature, in a dry glass container. This polymer precipitate was the stock of Biomer for the entire study.
Polyvinyl chloride (Bentley Laboratory Inc., Irvine, Calif.) was supplied in the form of "Implant-Tested" cardiovascular bypass tubing. Upon receipt, the tubing was stripped of all inked impressions by cutting those sections out and discarding them. The remainder was cut into small pieces and stored in the dark in a dry glass container at room temperature.
Polystyrene (Coming Glass, Coming, N.Y.) was supplied as sterile culture dishes or as 1.00-mm spherical beads (Sinclair-Koppers Co.). Polystyrene (PS) was chosen as a reference material due to its chemical similarity to pure PVC and since it is available in relatively large pure quantities. The PS beads were used as received, whereas the culture dishes were granularized and stored in the dark in dry glass containers at room temperature.
Polydimethylsiloxane (PDMSO) was supplied as nonreinforced medical grade subdermal implant Silastic sheeting or as Medical Adhesive 891 (both from Dow Coming Corp., Midland, Mich.). PDMSO was chosen because of its current usage in the biomedical field as a common subdermal implant material. PDMSO, of which Silastic is a type, is also a reference material of the National Heart, Lung and Blood Institute (22 Solutions [ 10% (w/v)] of Biomer and polyvinyl chloride were prepared by stirring resins in N,N-dimethylacetamide (spectral grade) for 12 to 24 h. The polymer solutions were filtered (0.22 ~m) to remove particulates. The filtered solutions were cast against cleaned glass plates. These cast solutions were then heated to 50°C in a vacuum oven, at atmospheric pressure, for 24 h to drive off the solvent. The films were then stripped from the plates and replaced in the heated vacuum oven (50°C, 20 t~m Hg Torr) for 24 h to remove all residual solvents.
A 10% (w/v) solution of polystyrene (PS) was made by stirring PS granules in dichloromethane (spectral grade) for 1 to 2 h. The PS solution was then filtered (0.22 tzm) and cast against clean glass plates. The cast solution was placed in a laminar flow hood for 24 h at room temperature to allow the solvent to evaporate. The resultant rind films were then removed from the plate support and placed under heated vacuum (50°C, 20 um Hg Torr) for 24 h to remove any residual solvent.
The substrate surfaces were cleaned following a protocol described elsewhere (24, 61, 62) . The procedure was utilized to remove surface contaminants in the micron range and larger prior to experimental use. All materials were handled with gloved hands or with metal forceps and cleaning was done in a clean room free from micron-sized particles.
Polystyrene beads, 1.00 mm diameter, were cleaned by the methodology of Coleman et al. (23) . Polystyrene beads were placed in an extraction thimble (fat-extracted cellulose, Whatman) and refluxed in a Soxhlet extractor with petroleum ether (reagent) for 24 h followed by drying under heated vacuum (50°C, 20 t~m Hg Torr) for at least 24 h.
Cleaned fused amorphous silica slides were treated for 5 min in oxygen plasma produced by a Plasmod (Tegal Corp., Richmond, Calif.) according to the methodology of King et al. (24, 61) . Slides prepared in this fashion were immediately used and were never stored for longer than eight hours in glass containers that had been cleaned in a similar fashion.
In order to produce a more hydrophobic surface, previously cleaned and radiofrequency glow-discharged silica slides were vapor-silanized according to the methodology of Hailer (25) using N-propyltriethoxysilane. This silanization procedure covalently links the silane groups to the surface of the silica slides, masking the hydrophilic silica surface. The resultant silica has N-propyltriethoxysilane covalently attached to the surface (NPS-silica).
Disposable polypropylene columns (0.8 × 20.5 cm, Kontex, Vineland, N.J.) were cut to 2-cm lengths and packed with either cleaned glass beads (1.00 to 1.05 mm diameter) or cleaned polystyrene beads (1.00 mm diameter). The glass bead columns were then subjected to polymer solution treatments to coat the beads with the desired polymer after a modification of the methodology of BrierRussell et al. (26) , described below.
Solutions [1% (w/vi] of Biomer in spectral grade N,N-dimethylacetamide, polyvinyl chloride in N,N-dimethylacetamide (spectral grade), polystyrene in dichloromethane (spectral grade), and Silastic adhesive (uncured) in toluene (spectral grade) were prepared and stored in sealed glass containers in a dark environment. These stock solutions were filtered (0.22 tsm) just prior to use. Using cleaned glass syringes, the solutions were injected slowly upward into the packed columns. The columns were continuously tapped to prevent or dislodge trapped air pockets. When the reservoir had approximately 5 ml of polymer solution, the solution was allowed to flow back down through the column, under gravity. The last remaining drops were then "wicked" from the bottom, via capillary action, with a clean dry cloth. Columns were stored covered at room temperature for 24 h to allow the solvent to evaporate. The columns were then placed under heated vacuum (50°C, 20/~m Hg Torr) for 24 h to remove all residual solvents. This solution injection/draining procedure was repeated five times to insure complete polymeric coverage of the glass beads.
Random columns were selected for observation and characterization by scanning electron microscopy and X-ray photoelectron spectroscopy. The columns were assumed to have a packing efficiency of 0.74 (a closepacked system) and thus a void volume of approximately 0.8 ml. The volume of the columns was 1.0 cm 3 and, assuming only point contact between spheres, yielded an effective surface area of 50 cm 2 (27) .
All substrate materials were characterized according to a modified version of the suggested Level II characterization of surfaces by the National Heart, Lung and Blood Institute (22). The materials were subjected to light microscopy, scanning electron microscopy, surface energetics characterization (Wilhelmy plate contact angle), and X-ray photoelectron spectroscopy (28, 29) .
The commercially available sodium salt of heparin was fractionated by gel permeation chromatography.
Samples of low-molecular-weight (LMW), high-molecular-weight (HMW), and commercial sodium heparin were then characterized by an independent laboratory. The molecular weight was determined by high-performance (pressure) liquid chromatography (HPLC) using dextrans of various molecular weight as standards, according to the methodology of Hurst et al. (30) .
The free amine groups on heparin were reductively methylated using a modification of an earlier protocol (31) patterned after Jentoff and Dearborn (32). The radiolabeled heparin was then lyophilized and stored at -10°C until used. Unless otherwise stated, all labeling procedures had an effective degree of labeling of approximately 0.8 labels per molecule.
Proteins of interest were iodinated using immobilized lactoperoxidase-glucose oxidase with labeled sodium iodide. From 0.25 to 1.00 g of protein was dissolved in 0.375 ml PBS, pH 7.4. A suspension of immobilized lactoperoxidase and immobilized glucose oxidase (Enzymobeads, Bio-Rad, Richmond, Calif.) in 0.25 ml distilled water (rehydrated 24 h prior to use) was added to the protein solution. Then, 1.0 mCi Na~25I (New England Nuclear, Boston, Mass.) was added (specific activity 17.4 Ci/mg and concentration 100 mCi/ml) to this reaction mixture. Finally, 0.125 ml, of a freshly prepared solution of 1% (w/v)/3-D(+) glucose (Sigma) in water was added to the reaction solution. The solution was capped and allowed to stand unagitated for 30-35 rain. The reaction was stopped by passing the reactants through two previously characterized Sephadex G-25 columns. The labeled protein eluted entirely in the void volume while the Enzymobeads did not elute at all. The remaining reactants and unwanted by-products eluted in the last portion of the total volume. The protein concentration was determined by UV spectroscopy (Perkin-Elmer Lamda 7 UV-Vis spectrophotometer). All radiolabeled proteins were freshly prepared and were discarded after 24 h. All iodinations had a degree of labeling of approximately 0.5 labels per molecule.
In order to insure that the iodination procedure did not denature the proteins, all radioiodinated proteins were characterized by ultraviolet spectroscopy, fluorescence spectroscopy and polyacrylamide gel electrophoresis. The stability of the iodinated species, with respect to the substituted iodine, was deterrnined and any quenching effects of the iodine label on the fluorescence emission and UV absorbance was noted.
Two systems of equilibrium dialysis were utilized to detect heparin binding to proteins in solution. The first was a system wherein dialysis tubing (Spectrapor 6, Spectrum Medical Industries, molecular weight cutoff25,000) was used to house both the protein and heparin, and the second was a system where the same dialysis tubing was cut into sheet form and clamped between two identical chambers. The advantage of the second method, when compared to the first, is that it was easier to insure that leakage into the buffer reservoir did not occur. The first system utilized a 2-ml reservoir and a 6-ml buffer surround. The second system consisted of two identical chambers of 5 ml volume each separated by dialysis sheeting.
The systems were characterized (33) in separate control experiments by placing tritiumlabeled heparins (LMW, HMW, and commercial sodium heparin) with phosphatebuffered saline (PBS), pH 7.4 (2 mM KH2PO4, 8 mM Na2HPO4, and 145 mM NaC1), in the reservoirs and allowing them to diffuse until equilibrium was reached.
Protein binding to heparin was determined for all three heparins by adding the proteins and 3H-heparin in the same reservoir (33) so that the final concentration of protein was 1.5 X 10 -6 M. The final 3H-heparin concentration was 50, 25, and 10 tzg/ml, in separate experiments. The buffer was mildly stirred (system 1) or the entire system was rotated gently (system 2) on a laboratory rotator for 24 h, at which time the samples were taken. The extent of binding and binding kinetics were determined by comparing the amount of 3H-heparin on the reservoir side versus the unbound Protein adsorption onto cleaned Biomer, polyvinyl chloride, polydimethylsiloxane (Silastic), amorphous silica, and polystyrene substrate disks was done in an adsorption cell. The cells themselves were 1-ml disposable cuvettes capped with clean 00 corks. Tygon tubing was introduced into bored holes in the corks and stoppered on the outer ends with three-way stopcocks.
Substrates were introduced into the cells with clean forceps and the cells then corked. The closed cells were then primed with degassed PBS (pH 7.4) until all air was removed. The cells were allowed to sit at room temperature for at least 1 h prior to the introduction of labeled protein solution. Radiolabeled protein solutions were then introduced by injec- tion from clean disposable syringes. Ten milliliters of protein solution was injected into the cell at the rate of 40 ml/min to remove all priming buffer and to introduce the protein solution in desired concentrations. Care was taken so as not to introduce any air into the system. The cells were then allowed to remain stationary, at room temperature, for up to 24 h. To terminate protein adsorption each cell was flushed with 30 ml PBS buffer at 60 ml/ rain, to insure that the substrates were not removed through a protein-solution/air interface. Previous studies with priming solution of Blue Dextran 2000 (Pharmacia Fine Chemicals), using light spectroscopy (639 nm), indicated that the dextran was removed after a 5-to 6-ml flush, at 40 ml/min. Substrates were then removed and placed in dry scintillation vials. Adsorbed protein concentrations were determined by gamma counting on a gamma radiation detector.
Desorption of the protein from the substrates was determined by allowing preadsorbed protein films to desorb in fresh PBS buffer, for up to 24 h, in new vials. The cells were then flushed to remove all desorbed protein. Remaining protein concentrations were determined by 3' radiation counting. Verification of the concentration of initially adsorbed protein layer required that the desorbed protein solution, flushed at the termination of the experiment, be counted in similar fashion.
Desorption of adsorbed radioiodinated proteins was also done in freshly prepared bovine platelet-poor plasma (PPP). Fresh whole slaughterhouse blood was collected and mixed in a 9:1 (v/v) ratio with a 3.8% (w/v) solution of sodium citrate (reagent grade) in water. PPP b For confidence levels, see Fig. 1 .
was prepared by centrifugation of the whole blood for 20 min at 1300g force. PPP was then pipetted off and used immediately. The desorption experiments with PPP was the same as above, except that PPP was used as the desorption medium. Flushing was still done with PBS buffer. Maximum desorption time was 8 h with PPP. Native proteins were adsorbed onto clean Biomer, PVC, PS, PDMSO, and glass substrate disks (planchettes) from 0.3 mg/ml protein solution left for 24 h. After buffer flushing, 10 ml of 0.1 mg/ml solution of either LMW, HMW, or commercial ~4C-heparin, in PBS, was injected into the cell. The lac-heparin was allowed to interact with the adsorbed protein layer for 1 h whereupon the cells were flushed with 30 ml PBS buffer at 60 ml/min to remove all desorbed protein and unbound heparin. The substrates were then air-dried at room temperature and the amount of bound ~4C-heparin determined by counting on a "planchet type" gas ionization radiation detector (Internal Proportional Counter, Eberline 2200) for 5 min (high voltage at 96.75 V, window at 96 V, and threshold at 40 V).
Quantitation was clone by subtraction of CPM of 14C-heparins on controls (no adsorbed protein) from CPM of 14C-heparins bound to adsorbed protein substrates. This modified CPM was further corrected by dividing by the efficiency, found from a calibrated 7-source, yielding effective degradations per minute (DPM). This DPM value was then divided by the specific activity to yield the amount of 14C-heparin bound.
Previously prepared columns of polystyrene beads, glass beads, and polymer-coated glass beads of Biomer, polyvinyl chloride, and polydimethylsiloxane were primed, from the bottom, with PBS for 1 h. Excess buffer was then pipetted off and 10 ml of native protein solution (0.3 mg/ml) was introduced the same way as was the buffer. Proteins were allowed to adsorb for 24 h. After having excess protein solution pipetted from the column reservoir, the columns were then flushed with 30 ml PBS buffer. Solutions (0.1 mg/ml) of 14C-labeled heparin of commercial molecular weight, were then introduced, as above, in 10-ml aliquots and allowed to interact for up to 8 h.
Kinetics of ~4C-heparin binding were monitored by solution depletion techniques. The stock 14C-heparin solution activity was compared to the activity of 100-#1 samples drawn from the bottom of the column. Activity and quantitation were accomplished by liquid scintillation counting.
Release (desorption) of 14C-heparin was done in both PBS buffer and bovine platelet poor plasma (PPP). At binding equilibrium, the 14C-heparin solution was pipetted from the reservoir and the column flushed with 30 ml PBS buffer. Again, excess buffer was removed from the reservoir. At this time PBS buffer release of t4C-heparin was initiated. Samples were taken by injecting 1 ml PBS buffer from below and removing the same volume of buffer from the reservoir. Desorption was allowed for up to 24 h. Release of 14C-heparin in bovine PPP was done as above except that PPP was introduced by a second flush of 20 ml plasma to remove excess PBS buffer. Samples were taken in a similar manner. Plasma release studies were done for up to 8 h.
All plasma and buffer samples were counted by liquid scintillation counting.
The total amount of 14C-heparin released could be due to: (a) released 14C-heparin from nondesorbing protein, CR; and (b) "released" heparin still bound to desorbed protein, CB. If CB is equal to the amount of desorbed protein (Cp) (previously determined) then the true amount of 14C-heparin actually released from protein, C, is given by
where CH=CR+CB = Amount determined by liquid scintillation counting.
Fresh human whole blood was obtained from healthy donors and immediately mixed in a 9:1 (v/v) ratio with a 3.8% (w/v) solution of sodium citrate (Reagent grade). Platelet poor plasma (PPP) was obtained by centrifugation of the whole blood for 10 min at 2200g force. The PPP was decanted offand used immediately or stored frozen for up to 2 weeks. Human PPP was introduced into buffer primed Biomer columns according to the methodology previously discussed. PPP was allowed to remain in the columns for 1 h to allow for plasma protein adsorption, then the columns were flushed with 30 ml PBS (pH 7.4) at approximately 60 ml/min. Solutions of commercial lac-heparin (0.1 mg/ml) were introduced and the kinetics of binding monitored for up to 24 h via solution depletion. Release of 14C-heparin was done as previously described in both PBS buffer and human PPP.
Activated partial thromboplastin time (APTT) and anti-Xa assays (34) were performed to determine the activity/presence of the bound and/or released heparins from substrates coated with plasma fibronectin and pooled human PPP.
RESULTS AND DISCUSSION
The substrate surfaces characterized were clean. There were no observed particulates or chemical impurities in the matrix. Most of the surfaces were macroscopically smooth. However, some roughness was observed on Biomer, Silastic, polystyrene beads, and glass bead surfaces at high magnification (36) . All surfaces were wettable to different extents (see Table I ) as indicated by the receding angle observed via Wilhelmy plate energetics. The substrate surfaces were clean and chemically accounted for by XPS examination. The solution technique of coating the glass bead supports was shown to be complete by scanning electron microscopy and XPS analyses (36) .
Utilizing high-pressure liquid chromatography, the fractionated heparins were characterized by reference to known dextran molecular weights. This methodology yields the molecular weight relative to dextrans; therefore, the absolute molecular weights are still unknown. Another disadvantage to this methodology is that the molecular weight distribution (i.e., weight average molecular weight, number average molecular weight) remains unresolved. However, the relative values were consistent and thus considered reliable. Since heparins are chain-like structures and not globular in nature, like dextrans, it was necessary to multiply the values obtained by an empirically derived factor (30) to compensate and yield more "accurate" relative molecular weights. The results are listed in Table II for LMW fractions, medium-molecular-weight fractions (not utilized), and HMW fractions. The average molecular weight for commercial heparin was determined from the values listed.
The optical properties of the labeled proteins, studied here, which are indicative of conformation, seem to be identical to the native proteins (36) . Also, the electrophoretic mobility was unchanged, which indicates similar conformation and that no fragmentation occurred during iodination (64) . Even so, it still cannot be concluded that the iodinated protein is equivalent to the native structure. Indeed, iodide has a relatively large atomic radius and is extremely large when compared to the hydrogen atomic size that it has been substituted for. In this study the iodination performed was done under conditions much milder than the manufacturers' recommendations for iodination and the resultant specific labeling was much lower than those reported by the manufacturers. Since there was only up to one label per protein considered (usually only 0.5), it is highly unlikely that the same tyrosine is labeled every time in the respective proteins considered. This being the case, perhaps the localized iodine effects are either masked by the large surrounding host or so small that accommodation by the relatively immense protein is accomplished without any macroscopically observable effects. In either case, one may be certain that the electronegativity and size of the iodide substitution has a massive localized effect. It is assumed While it is customary to report K~soc in terms of moles per liter (M), due to the polydispersity ofheparin and the heparin fractions used herein, it was felt that reporting Kassoc in terms of grams per liter is much more descriptive (see Table III ).
In this study, each adsorption was run at least three times using ratios of labeled to un- tion onto amorphous silica, Biomer, Silastic, and cellulose acetate (7) . Similarly, concerning labeled fibrinogen, this study showed no preferential adsorption while others (7) have shown preferential adsorption elsewhere. It should be noted, however, that these substrate surfaces here are different than those previously reported. Figure 2 shows the adsorption isotherms of 125I-labeled albumin on the polymeric substrates utilized. The adsorbed amount, for a 0.3 mg/ml solution ofiodinated albumin, falls very near to the reported values of others (44) (45) (46) (47) (48) (49) (50) and nearly equal to the approximate 0.7 #g/cm 2 monolayer concentration reported on polystyrene and polyurethane substrates (45, 46). Assuming that the iodinated albumin undergoes no multilayering, significant structural changes upon adsorption, and that surface irregularities can be neglected (36) on the polyvinyl chloride (PVC) or Silastic surfaces, then this study's albumin coverage on the substrates can be taken as follows: (a) polystyrene, 97% coverage; (b) PVC, 77% coverage; (c) Silastic, 86% coverage; and (d) Biomer, 100% coverage. Adsorption of albumin to a lesser extent on polyurethanes or polystyrenes under similar conditions has also been shown elsewhere (45) . The isotherms of iodine-labeled fibrinogen (Fg) are shown in Fig. 3 . The adsorption values are similar to those reported in the literature (45, 51) and the similar lack of a saturated monolayer on the surface at these concentrations is well depicted. Monolayer coverage is reported to be in the range of 0.8 to 1.2 ~g/ cm 2 for Fg. If a 1.0 ~zg/cm 2 coverage is taken as 100% monolayer coverage, then the percentage coverage of Fg on these substrates can be given as: (a) polystyrene, 59%; (b) PVC, 79%; (c) Silastic, 59%; and (d) Biomer, 59%.
Iodine-labeled fibronectin (Fn) adsorption isotherms are given in Fig. 4 for the polymeric substrates and hydrophilic silica. The values listed are comparable to those given in the literature (52-60) using similar concentrations. Except for the complete isotherms given by Bornzin and Miller (50) , much of the adsorption work has ignored the possibilities of preferential adsorption of labeled Fn and/or the air-solution interface. These problems, in addition to incompletely characterized substrates, results in a large uncertainty as to actual monolayer coverage values. Therefore, the values of Fig. 4 will be assumed to be 100% monolayer coverage, since no preferential adsorption was seen to occur in this study. The large difference in plateau values of the sub- lier for Fn adsorption onto hydrophobic silica surface (53, 61) . Figure 5 shows kinetics of adsorption for 125I-Fn. In all cases steady-state values were reached within 2 h, except for hydrophilic silica and within 1 h for adsorption onto PVC. 125I-Fn adsorption onto PVC can be fit to an ideally controlled process by diffusion, for the first 30 min. Thereafter, for the next 5 to 7 rain a change in the type of adsorption was seen and then the onset of steady state followed. This pattern was quite similar to the pattern observed in the total internal reflection fluorescence (TIRF) mode for hydrophobic NPS-silica except for the concentration of Fn adsorbed under those conditions was calculated to be much less (61) . In the TIRF mode, the Fn adsorbed onto the hydrophobic silica was observed to be in a different environment (conformation) than that on the hydrophilic silica. It was thus hypothesized that this conformational change accounted for the increased accommodation of Fn on the hydrophobic silica surface. It is probable then that the differences in the adsorption rate and concentration of Fn on PVC, as compared to the other substrates was due to it also being in a different conformation on that substrate. It is interesting to note that the adsorption kinetics of ~25I-labeled Fn onto hydrophilic silica appears very similar to the second time phase of the TIRF monitoring of Fn adsorption on the same surface (61) . The static adsorption seemed to take longer; however, this was not It is tempting to say that most of the static adsorption processes depicted here deviate from an ideal diffusion-controlled process.
This cannot be said for certain, however, since the first samples were taken (experiments terminated) after 15 rain of adsorption time. It is probable that diffusion does have a part in the very early stages of the adsorption process (63) only it was not observed here due to the sampling protocols. Desorption of adsorbed 125I-Fn monolayer films is shown in Fig. 6 in buffer and plasma solutions. The monolayers were adsorbed from 0.3 mg/ml solutions of radiolabeled protein. Fibronectin shows significant losses on PVC surfaces with both PBS and plasma. However, the other surfaces show only a t0 to 15% loss in PBS and plasma.
The adsorbed Fn generally appears quite stable. The PVC, however, shows FIN monolayer losses of 40% in plasma and 60% in PBS buffer. This is due perhaps to the nature of the adsorption process. Adsorbing quite rapidly (diffusion controlled), the protein may be in a conformation that is a steady-state equilibrium with the Fn "sink," yet not in a preferred orientation. Under desorption conditions, this steady-state condition is no longer the equilibrium state and thus the surface concentration is reduced considerably possibly to accommodate reorientation.
The kinetics of binding and release of 14C-labeled heparin with Fn-coated substrates are shown in Figs. 7 and 8 , respectively. 14C-heparin solutions were not observed to be significantly depleted when passed over columns preadsorbed with monocomponent fibrinogen and albumin solutions, over the same period of time (36) .
The kinetics of binding for adsorbed fibronectin (see Fig. 7) show that steady state occurred in all cases within 1 h. The concentra- Figure 8 shows the release of bound 14C-heparin in PBS buffer and plasma. In all systems, the total amount of released heparin did not equal that predicted by Eq. [3] , which accounts only for released protein (see Fig. 6 ). This may be explained by several possible mechanisms of which two are discussed: (a) heparin binding to adsorbed fibronectin alters the adsorbed protein sticking coefficient thus making it adhere more tenaciously to the various substrates. Perhaps by allosterically binding heparin to the adsorbed protein, the resuiting conformational change in the protein gives it a better "foot hold" on the substrate surface. This aUosteric change in Fn induced by the binding of heparin has been suggested (64, 65) for the mechanism by which fibronectin increases its ability to bind to immobilized collagen and complex solution phase collagen; (b) solution-bound heparin may be released more readily and reorientation of the protein monolayer may accommodate the rebinding of the free heparin. This mechanism seems feasible for the PVC surface where Fn is apparently sterically hindered due to the high concentration of surface adsorbed Fn in comparison with other substrates; however, it is less likely for the other surfaces where the absorbed Fn is apparently more "spread out." In all cases, no more than 2% of the total ~4C-heparin was released in PBS buffer and no more than 17% of the total 14C-heparin was released in the plasma environment. The great increase in the plasma release of 14C-heparin was probably due to the binding of heparin to blood factors rendering them inactive, and to the bacteriological and enzymatic attack of the protein monolayer or bound heparin. Exchange of the adsorbed protein in plasma could also increase the amount of released heparin in a bound state to the original protein.
The results of 14C-heparin binding protein monolayers as determined by gas ionization counting of the 14C-label are given in Table  IV . For ease of comparison, the tabulated results from Figs. 2 through 8 are also given. All six binding sites for heparin on fibronectin, as determined by Scatchard analysis, were active and available in the adsorbed state for all substrates except PVC. The increased concentration of Fn adsorbed onto the PVC surfaces or its resultant different adsorbed conformation (64, 65) probably sterically blocked the majority of the binding sites in that system. It appears that two heparin binding sites are hindered on both sides of the protein dimer and that a third may be hindered somewhat on one of the sides. Most likely, energy supplied by thermal fluctuations or convective turbulence probably renders this one semihindered site somewhat available for heparin binding. This explains the molar ratio of one fibronectin to approximately 1.5 heparin molecules.
~4C-Heparin binding to the proteinaceous monolayer left after human serum interaction was not observed (36) . In columns with surface areas up to 100 cm 2, the introduced 14C-heparin solution did not decrease in activity over a 24-h period. Assuming that the protein monolayer is at least as stable as a composite of the aforementioned monocomponent systems (Table IV) of albumin, fibrinogen, and fibronectin in PBS (pH 7.4), the possibility of total protein desorption and thus undetected solution binding can be eliminated. After buffer flush, desorption/release was carried out in a buffer environment for 24 h or in a canine plasma environment for 8 h. All samples were I I I 4 6 equivalent to background counts or within the error of the standard deviation. Thus, it may be concluded that the proteinaceous monolayer cannot bind heparin and, therefore, must contain very little fibronectin or inhibited fibronectin which is unable to bind heparins. Activated partial thromboplastin time (APTT) assays for heparin are generally considered valuable; however, they are nonspecific in nature (66, 67) in that: (a) bound heparin and solution heparin may be treated equivalently and (b) any adsorption, and thus loss, of coagulation factors will prolong the resultant assay time. The results of APTT coagulation times done on plasma that had been in contact with polymer substrate discs, pretreated with adsorbed Fn and bound heparin fractions, are given in Table V . The assay showed generally that all the prebound heparin was available for prolongation of coagulation times. The excessive prolongation of some observed clotting times is probably due to the depletion of coagulation factors (68) . The depletion of these factors could occur by adsorption to container or substrate surfaces or inactivation by binding to either adsorbed or desorbed Fn molecules. If loss of coagulation factors were causing excessively prolongated coagulation times not accounted for by the heparin present, it would be magnified in systems with much larger surface areas. Figure 9 shows prolongation of clotting times with increasing plasma contact time on column control substrates preadsorbed only with fibronectin. The erratic behavior can be explained by the binding or adsorption and subsequent release or desorption with time, of coagulation factors. This behavior caused the scatter (SD) of times to be so great that the coagulation times could not be distinguished from those of the column substrate controls. Therefore, to determine the increase in coagulation times attributable to the bound and released heparin from the column experiments, heparin colorimetric assays run concurrently or at the end of the plasma incubation of the substrate columns had to be done.
Activated Factor X assay is very sensitive and specific for heparin in plasma environments (34) . The method involves the use of a chromogenic substrate ($2222) that is susceptible to the presence of Xa. Unknown concentrations ofheparin are introduced which bind to known quantities of Xa. The Xa-heparin complex is inactive toward the $2222 substrate. The remaining Xa activity is quantitated by amidolysis of the $2222 substrate. The amidolysis is stopped by the addition of acetic acid after a specified time. This methodology can detect 0.02 units of heparin per milliliter of plasma tested.
Concurrent with APTT testing of plasma subjected to column substrates, each sample was tested, in duplicate, for released heparin activity via activated Factor X assay. The resuits are given in Fig. 10 (also reference Table IV and Fig. 8) . The results correlated well with the data observed for heparin release in plasma. Small differences in the amounts of heparin released may be due to the different plasmas utilized in the two studies (bovine versus canine).
CONCLUSIONS
This in vitro study has shown several important aspects relating to localized heparin delivery at a foreign surface-blood interface. First, albumin, albeit a cartier of metabolic by-products and some anticoagulants, does not bind heparin at physiological pH in solution or in the adsorbed state. The same can be stated for fibrinogen. Plasma fibronectin, on the other hand, binds heparin in either state. Fibronectin was shown to have six binding sites for heparin which may be sterically blocked if fibronectin adsorbs in such a fashion as to increase the surface concentration of the adsorbed protein. Next, it has been shown that by using adsorbed fibronectin as an intermediate, it is possible to deliver heparin, prebound to the adsorbed protein, in concentrations up to approximately 0.2 ~g/cm 2 in a plasma environment. Also, active surfacebound heparin was maintained at approximately 83 to 99% of original-bound heparin concentrations for up to 6 to 8 h time. The stability of the Fn monolayer was increased by the binding of heparin, probably due to an allosteric change upon binding the drug moiety, increasing the sticking coefficient of Fn (64, 65) .
It is also interesting to note that human serum, allowed to adsorb onto Biomer surfaces, does not bind heparin even though fibronectin occurs in most healthy adults in the range of 300 to 500 t~g/ml plasma. Therefore, Fn appears not to be preferentially adsorbed from multicomponent systems. Or, if it is, it adsorbs from such systems in conformations unable to bind heparin. Comparing APTT results of the fibronectin-precoated substrates bound to heparin, to controls precoated with human plasma or fibronectin alone, showed that the fibronectin-heparin surface does not increase the intrinsic activation of the coagulation cascade but rather increases the relative normal coagulation times two to three times over those observed with monocomponent human plasma or fibronectin. When the APTT results of this fibronectin-heparin complex are compared to the albumin-heparin covalent conjugate (7, (18) (19) (20) (21) , it can be seen that the times are similar, indicating that both are effective in prolonging clotting times. However, the comparison of direct times is not the important factor; rather that both tend to double or triple their clotting times relative to controls is significant.
The trends observed throughout this section seem to indicate that the bound heparin is active in prolonging clotting times (APTT and Xa assays) and that the fibronectin adsorbed monolayer may indeed aid in reducing the intrinsic activation of Factor XII. Furthermore, the amount of heparin remaining bound to the monolayer is greater than predicted by protein desorption alone.
